8-K: BioMarin to Acquire Amicus Therapeutics for $4.8 Billion

BioMarin Pharmaceutical Inc. has entered into a definitive agreement to acquire Amicus Therapeutics for $14.50 per share in an all-cash transaction, totaling approximately $4.8 billion.

Summary

• BioMarin Pharmaceutical Inc. will acquire Amicus Therapeutics, Inc. for $14.50 per share in an all-cash transaction, valuing Amicus's equity at approximately $4.8 billion.
• The acquisition price represents a 33% premium to Amicus's closing stock price on December 18, 2025, a 46% premium to its 30-day volume-weighted average stock price, and a 58% premium to its 60-day volume-weighted average stock price.
• The Boards of Directors of both companies have unanimously approved the agreement, and Amicus's Board unanimously recommended that its stockholders vote to adopt the agreement.
• The transaction is expected to close in the second quarter of 2026, subject to regulatory clearances, approval by Amicus stockholders, and other customary closing conditions.
• Amicus's key products include Galafold (migalastat) for Fabry disease and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) for Pompe disease, which generated combined net product revenues of $599 million over the past four quarters.
• Amicus also holds U.S. rights to DMX-200, an investigational small molecule in Phase 3 development for focal segmental glomerulosclerosis (FSGS).
• Amicus has resolved patent litigation regarding Galafold, granting licenses to Aurobindo Pharma and Lupin Ltd. to market generic versions in the U.S. starting January 30, 2037.
• BioMarin intends to finance the acquisition through a combination of cash on hand and approximately $3.7 billion of non-convertible debt financing, with a bridge commitment from Morgan Stanley Senior Funding, Inc.
• Amicus's bylaws were amended on December 19, 2025, to establish Delaware courts or U.S. federal district courts as the exclusive forum for certain corporate actions and claims.

Sentiment

Score: 8

Explanation: The all-cash acquisition offers a substantial premium to Amicus shareholders and is expected to be financially accretive for BioMarin, expanding its rare disease portfolio and market reach. The resolution of patent litigation for a key product further de-risks the investment.

Positives

• Amicus stockholders will receive a significant premium of $14.50 per share in an all-cash transaction, representing 33% over the last close, 46% over the 30-day VWAP, and 58% over the 60-day VWAP as of December 18, 2025.
• The all-cash nature of the transaction provides certainty of value for Amicus stockholders.
• The acquisition is expected to accelerate BioMarin's revenue growth and strengthen its financial outlook, becoming accretive to Non-GAAP Diluted EPS within the first 12 months post-close and substantially accretive beginning in 2027.
• The resolution of Galafold patent litigation secures U.S. exclusivity for the product through January 30, 2037, providing a clear market runway.
• BioMarin's global commercial footprint and resources are expected to expand access to Galafold and Pombiliti + Opfolda for more patients worldwide.
• BioMarin has committed to deleveraging, targeting gross leverage below 2.5x within two years after the closing of the transaction.

Negatives

• Amicus Therapeutics will cease to exist as an independent publicly traded company.
• The cash payment received by stockholders will be a taxable event.
• There is inherent uncertainty for Amicus employees regarding future roles, operational details, and potential changes to facilities post-integration, despite initial assurances of no immediate changes.
• The transaction involves a significant amount of debt financing for BioMarin, approximately $3.7 billion, which will increase its leverage.

Risks

• The transaction may not be consummated within the anticipated timeframe or at all, due to failure to obtain regulatory clearances, stockholder approval, or other closing conditions.
• There is a possibility that competing acquisition proposals could emerge, potentially delaying or altering the current agreement.
• Governmental entities may prohibit, delay, or refuse to grant approval for the transaction, or grant approval subject to adverse conditions or limitations.
• The transaction could adversely affect relationships with employees, customers, suppliers, other business partners, or governmental entities, including employee retention.
• BioMarin may not realize the potential benefits of the transaction, or the integration of Amicus may be more difficult, time-consuming, or costly than expected.
• The transaction could disrupt management's time from ongoing business operations and current plans.
• Changes in Amicus's business during the period between announcement and closing could impact the transaction.
• Legal proceedings and/or regulatory actions related to the transaction could be instituted.
• The effects of industry, economic, or political conditions outside the companies' control could impact the transaction.

Future Outlook

BioMarin expects the acquisition to accelerate its revenue growth and strengthen its financial outlook, increasing its long-term CAGR through 2030 and beyond. The transaction is anticipated to be accretive to Non-GAAP Diluted EPS within the first 12 months post-close and substantially accretive beginning in 2027. BioMarin targets gross leverage below 2.5x within two years after closing. Amicus's medicines are expected to reach more patients globally due to BioMarin's greater resources and scale.

Management Comments

• Alexander Hardy (BioMarin President and CEO): "BioMarin's scale of operations, including our global commercial footprint and industry-leading, in-house manufacturing capabilities make the combination of these companies an exceptional strategic fit."
• Alexander Hardy (BioMarin President and CEO): "Immediately upon close, this transaction is expected to accelerate BioMarin's revenue growth and strengthen our financial outlook, delivering significant value to patients, employees and stockholders."
• Bradley L. Campbell (Amicus President and CEO): "I am enormously proud of our Amicus team. Together with our partners in the rare disease community, we created a truly patient-centric biotech and successfully developed two transformative medicines for people living with rare diseases, which impacted the lives of more than 3,400 patients around the world."
• Bradley L. Campbell (Amicus President and CEO): "With BioMarin's unwavering commitment to patients, along with greater resources and scale, Amicus medicines will reach even more patients around the world, faster. We are confident that this agreement is in the best interests of our shareholders by providing compelling, certain and premium value, and will accelerate progress for the rare disease community."

Industry Context

The acquisition strengthens BioMarin's position as a leader in rare diseases, particularly in lysosomal storage disorders, by adding two marketed therapies (Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease) and a Phase 3 candidate (DMX-200 for FSGS). This aligns with a broader industry trend of consolidation and strategic acquisitions to expand product portfolios and leverage larger commercial footprints for rare disease treatments. The resolution of patent litigation for Galafold provides long-term market exclusivity, a critical factor in the pharmaceutical industry for revenue predictability.

Comparison to Industry Standards

• The acquisition premium of 33% to Amicus's last close, 46% to 30-day VWAP, and 58% to 60-day VWAP is a substantial premium, generally considered attractive for target company shareholders in biotech M&A.
• BioMarin's commitment to deleveraging to <2.5x gross leverage within two years post-close is a common financial target for large pharmaceutical companies undertaking significant acquisitions, demonstrating financial discipline.
• The resolution of patent litigation for Galafold, securing U.S. exclusivity until January 30, 2037, provides a clear runway for BioMarin to maximize revenue from this asset, which is a key de-risking factor in pharmaceutical acquisitions.
• The combined net product revenues of $599 million over the past four quarters for Galafold and Pombiliti + Opfolda indicate a significant revenue stream being added to BioMarin's portfolio, comparable to mid-to-large cap rare disease product revenues.

Management Changes

Corporate Governance

Legal Proceedings

• Resolution of patent litigation brought by Amicus against Aurobindo Pharma and Lupin Ltd. concerning Abbreviated New Drug Applications for generic Galafold 123 mg capsules.
• Amicus entered into License Agreements with Aurobindo and Lupin, granting them licenses to market generic versions of Galafold in the United States beginning on January 30, 2037.
• All ongoing Hatch-Waxman litigation between Amicus and Aurobindo and Lupin regarding Galafold patents in the U.S. District Court for the District of Delaware will be terminated.

Stakeholder Impact

• Shareholders: Will receive $14.50 per share in cash, representing a significant premium over recent trading prices. The cash payment is taxable.
• Employees: Amicus and BioMarin will operate as separate entities until the expected closing in Q2 2026. No immediate changes to benefits are anticipated. 2025 bonuses, 2026 merit increases, and approved promotions for January 2026 will proceed. Unvested RSUs and in-the-money stock options will be cashed out at closing. Severance plans for change in control will be honored. Most hiring will be paused, and future operational details and facility changes will be determined post-integration.
• Patients: Amicus's medicines (Galafold, Pombiliti + Opfolda) are expected to reach more patients globally due to BioMarin's greater resources and scale.
• Customers, Suppliers, and Partners: Current contracts and points of contact will remain the same until the closing of the transaction, with no immediate changes expected in working relationships.

Next Steps

• Amicus will prepare and file a preliminary proxy statement with the SEC within 20 business days after December 19, 2025.
• Amicus will establish a record date, duly call, convene, and hold a special meeting of its stockholders to vote upon the adoption of the Merger Agreement.
• Amicus will mail the definitive Merger Proxy Statement to its stockholders as soon as practicable after the SEC Clearance Date.
• BioMarin and Amicus will continue to operate as two separate, independent companies until the transaction closes.
• Integration planning between the two companies will commence after the deal closes.
• BioMarin targets achieving gross leverage below 2.5x within two years after the closing of the proposed transaction.
• Amicus will deliver a customary payoff letter for its Senior Secured Term Loan Agreement to Parent at least three business days prior to the Closing Date.
• Amicus will provide a written notice of prepayment for its Senior Secured Term Loan Agreement at least five business days prior to the Closing Date.
• Parent will effect the repayment in full of all outstanding indebtedness under the Senior Secured Term Loan Agreement on the Closing Date.
• Amicus will cooperate with BioMarin to delist its shares from Nasdaq and deregister them under the Exchange Act as promptly as practicable after the Effective Time.

Key Dates

Recommendation

The all-cash acquisition at a substantial premium (33% over last close, 46% over 30-day VWAP, 58% over 60-day VWAP) provides immediate and certain value to Amicus shareholders. The unanimous approval by both boards and the clear path to closing in Q2 2026, without financing conditions, significantly de-risks the investment for current shareholders. The resolution of Galafold patent litigation further solidifies the value of a key asset, making it a compelling opportunity for investors to capture the premium.

Keywords

Merger, Acquisition, Biotechnology, Rare Disease, Fabry Disease, Pompe Disease, Galafold, Pombiliti, Opfolda, DMX-200, BioMarin, Amicus Therapeutics, Pharmaceutical, Healthcare, M&A